Brain trauma affects millions. Learn about traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) and how they impact civilians and Veterans.
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Our approach is to build enabling platforms with strategic partners and to adopt a team science approach to fast-track solutions in years, not decades.
Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role
Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact. In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health.
Peter Hoehn joins Cohen Veterans Bioscience (CVB) as Executive Vice President, Strategic Marketing, Development, and Impact. In this newly created role, Hoehn will lead the External Affairs, Communications, and Development functions for New York-based non-profit CVB which is dedicated to advancing brain health. Hoehn will report to CVB Founder, CEO and President Dr. Magali Haas, MD, PhD.
Peter Hoehn is a proven healthcare business leader with 25+ years’ experience in a variety of commercial and strategy roles, predominantly at Johnson & Johnson. Hoehn was most recently Head, Commercial Strategy for J&J Science for Minds, a new organization focused on innovative development models and digital solutions to address serious mental illness and dementia. In this position he developed the strategy, portfolio recommendations, investment approach, external collaborations, and business models for new mental health and brain health digital business ventures.
“We are thrilled to have Peter join CVB in this new and important leadership role. I have had the privilege of partnering with Peter to advance brain therapeutics during our joint tenure at Johnson & Johnson and, more recently, in his capacity on the Steering Committee of the CVB-led Brain Health Nexus initiative. I am certain he will add impactful healthcare business expertise to our organization at a time of intense growth and development,” said Dr. Haas.
Throughout his career Peter has demonstrated the ability to develop insight-driven strategies in complex markets and mobilize internal and external partners to achieve results. He brings broad-based commercial, strategy and leadership experiences across Pharmaceuticals, Diagnostics, Digital Health, and Precision Medicine, including brand positioning and messaging, reimbursement and market access, global launches, organizational capability building, business model innovation, new opportunity evaluation, business development, and policy.
Peter started his career as a corporate lawyer and entered the pharmaceutical industry as an attorney for Bristol Myers Squibb. After a short time as a lawyer Peter moved into various strategy, marketing, and sales management roles at BMS before joining Johnson & Johnson in 2003.
Peter received a BA in Government and Economics from the College of William and Mary, and a JD from New York University.
Cohen Veterans Bioscience and 22 Jumps Announce Parachuting with Purpose: Recognizing the Epidemic of Veterans Suicide as a Result of Traumatic Brain Injury (TBI) and PTSD
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.